Poltreg S.A. Logo

Poltreg S.A.

PTG | WAR

Overview

Corporate Details

ISIN(s):
PLPLTRG00012 (+2 more)
LEI:
259400XSAJTERJ42VZ86
Country:
Poland
Address:
GDAŃSK BOTANICZNA 20, 80-298 GDAŃSK
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Poltreg S.A. is a clinical-stage biotechnology company pioneering the development of T-regulatory cell (Treg) therapies for autoimmune diseases. The company possesses one of the most advanced pipelines of cell therapies in this field. Its lead asset, PTG-007, is a potential disease-modifying treatment for Type-1 Diabetes and Multiple Sclerosis. Poltreg is also developing engineered CAR-Tregs for conditions including MS and Amyotrophic Lateral Sclerosis (ALS). With over 17 years of experience, the company was the first to administer Tregs to a patient and operates its own world-class manufacturing facilities to support its clinical programs.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Poltreg S.A.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-03 10:39
Regulatory News Service
Warunkowe przyznanie patentu przez Koreański Urząd Patentowy w projekcie terapi…
Polish 1.7 KB
2025-08-04 14:37
Legal Proceedings Report
Podanie pierwszemu pacjentowi terapii w ramach badania klinicznego fazy II w pr…
Polish 2.8 KB
2025-07-31 08:50
Legal Proceedings Report
Otrzymanie od FDA protokołu z podsumowaniem spotkania pre-IND - Content (PL)
Polish 2.0 KB
2025-07-29 14:05
Regulatory News Service
Otrzymanie Certyfikatu Dobrej Praktyki Wytwarzania od Głównego Inspektora Farma…
Polish 1005 bytes
2025-06-23 15:30
Regulatory News Service
Warunkowe przyznanie europejskiego patentu dotyczącego metody ekspansji ex vivo…
Polish 884 bytes
2025-06-13 15:56
Foreign Filer Report
Rejestracja spółki zależnej Immuthera w USA - Content (PL)
Polish 784 bytes
2025-05-21 12:30
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Zgromadze…
Polish 2.3 KB
2025-05-20 22:12
M&A Activity
Warunkowe przyznanie patentu przez Australijski Urząd Patentowy w projekcie ter…
Polish 1.4 KB
2025-05-20 22:12
M&A Activity
Warunkowe przyznanie patentu przez Australijski Urząd Patentowy w projekcie ter…
Polish 1.3 KB
2025-05-20 15:45
Remuneration Information
Sprawozdanie RN o wynagrodzeniach
Polish 1.2 MB
2025-05-20 15:45
Post-Annual General Meeting Information
Podjęte Uchwały
Polish 184.3 KB
2025-05-20 15:45
Post-Annual General Meeting Information
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie PolTREG S.A. w dniu 2…
Polish 729 bytes
2025-05-19 23:25
Regulatory News Service
Warunkowe przyznanie patentu przez Japoński Urząd Patentowy w projekcie terapii…
Polish 1.6 KB
2025-05-19 11:17
Board/Management Information
CV
Polish 1.2 MB
2025-05-19 11:17
Board/Management Information
Zgłoszenie kandydata na Członka Rady Nadzorczej PolTREG S.A. - Content (PL)
Polish 1.7 KB

Automate Your Workflow. Get a real-time feed of all Poltreg S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Poltreg S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN